Abstract:
Objective To study the efficacy and safety of colloidal bismuth tartrate combined with mesalazine in the treatment of ulcerative colitis.
Methods A prospective, randomized, open and controlled study was used in this study, which was randomly divided into two groups: group A and group B. Group A was treated with colloidal bismuth tartrate combined with mesalazine(colloidal bismuth tartrate capsule, 165 mg, 4 times a day, 1 time half an hour before meal and 1 time before sleep, 4 weeks of treatment, 1 g mesalazine tablet, 3 times a day, 8 weeks of treatment). Group B was treated with mesalazine only(1 g mesalazine, 3 times a day, 8 weeks of treatment). The relief of diarrhea symptoms, the total clinical effect, the healing rate of mucosa under endoscopy and adverse reactions were observed.
Results A total of 60 patients were included in the study, including 32 men and 28 women, aged 18-65 years, with a course of 6 months-4 years, an average weight of 56.5 kg, 20 cases of proctitis, 40 cases of left colitis, 25 cases of mild colitis and 35 cases of moderate colitis.The clinical characteristics of the two groups were basically similar at baseline.Relief of diarrhea symptoms: compared with group B, the recovery time of diarrhea symptoms in group A [(7.1±4.8)days vs.(11.7±4.6)days]and the disappearance time of mucopurulent bloody stool(8.9±5.6)days vs.(13.3±4.7)days]were significantly shorter(P<0.05). Total clinical efficacy: group A(23 cases of clinical remission, 5 cases of clinical response, 2 cases of ineffectiveness)was significantly better than group B(14 cases of clinical remission, 11 cases of clinical response, 5 cases of ineffectiveness, P<0.05). Adverse reactions: gastrointestinal reactions: the number of cases of upper abdominal discomfort, heartburn, nausea and other reactions in group A(2 cases)was less than that in group B(3 cases), and no other adverse reactions were found, while in group B, increased frequency of watery stools was found in 1 case, and rash in 1 case.The liver and kidney function was normal in both groups.
Conclusion Colloidal bismuth tartrate combined with mesalazine in the treatment of ulcerative colitis can quickly relieve diarrhea symptoms and improve clinical efficacy.
Key words:
Ulcerative colitis,
Colloidal bismuth tartrate,
Mesalazine
Xueliang Jiang, Yuting Guo, Yang Wang. A randomized controlled study of colloidal bismuth tartrate combined with mesalazine in the treatment of ulcerative colitis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2020, 10(02): 70-73.